SAGE - Sage Therapeutics, Inc.
| Previous close | 162.090 |
| Open | 162.870 |
| Bid | 160.020 x 900 |
| Ask | 167.160 x 1200 |
| Day's range | 162.240 - 163.922 |
| 52-week range | 59.570 - 195.970 |
| Volume | 7,066 |
| Avg. volume | 489,773 |
| Market cap | 7.549B |
| Beta | 3.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.223 |
| Earnings date | 7 Aug 2017 - 11 Aug 2017 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 206.79 |
- Market Realist•2 days ago
SAGE Therapeutics’ NMDA Receptor–Based Portfolio
As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.
- Market Realist•2 days ago
SAGE Therapeutics’ GABA Receptor–Based Portfolio
As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.
- Market Realist•5 days ago
A Look at SAGE Therapeutics’ Product Portfolio
SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.
- Market Realist•5 days ago
SAGE Therapeutics’ Strategic Collaboration with Shionogi
On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.
- Market Realist•5 days ago
SAGE Therapeutics’ Stock Performance and Estimates in June
SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.
- MarketWatch•6 days ago
Sage shares drop 3% after $90 mln Shionogi deal for key drug
Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.
- Business Wire•6 days ago
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.
- Investor's Business Daily•7 days ago
Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug
Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.
- Motley Fool•8 days ago
Here's Why Sage Therapeutics Rose as Much as 20.3% Today
The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.
- Simply Wall St.•8 days ago
Is Sage Therapeutics Inc’s (NASDAQ:SAGE) Liquidity Good Enough?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Sage Therapeutics Inc (NASDAQ:SAGE), with a market capitalization of US$6.92B, rarely draw their attention from the investingRead More...
- Motley Fool•8 days ago
Why Tesla, Sage Therapeutics, and Lands' End Jumped Today
Find out which of these stocks made the biggest move higher.
- Investor's Business Daily•8 days ago
Why This Biotech Company Is Bounding Closer To A Breakout
Sage Therapeutics bounded closer to a break out Tuesday after the biotech company outlined its expedited path to approval for a depression treatment.
Bloomberg•8 days agoSage Therapeutics Rises After Depression Study Moves to Fast Lane
Sage Therapeutics Inc. climbed the most in two months after the U.S. Food and Drug Administration approved an expedited development plan for what the company says could be a practice-changing depression treatment. The biotechnology company only has to run a single 450-patient trial, which will allow for a compact, reasonably cost-efficient program that can assure both safety and effectiveness, Chief Executive Officer Jeff Jonas said in an interview. The medicine, SAGE-217, and the study design are different from those that have haunted psychiatric drugs in the past, according to Jonas.
- CNBC•8 days ago
Sage shares surge 15% after FDA OKs expedited depression drug development
Sage Therapeutics says the FDA has cleared it to expedite development of its drug to treat major depressive disorder and postpartum depression.
- MarketWatch•8 days ago
Sage shares surge 4.5% on plan to expedite drug development for two types of depression
Sage Therapeutics Inc. shares surged 4.5% in premarket trade Tuesday on news that the company met with the Food and Drug Administration and now plans to expedite development of its SAGE-217 drug in two areas of depression, major depressive disorder and postpartum depression. Sage plans one new phase 3 trial in major depressive disorder, which will likely begin in the second half of this year, to support a FDA filing for the indication. It also plans to use an ongoing trial for postpartum depression, for which early results are expected in the fourth quarter, to support another filing.
- Business Wire•8 days ago
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA). This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). The expedited development plan for SAGE-217 includes a single additional placebo-controlled Phase 3 pivotal trial in patients with MDD and the ongoing placebo-controlled trial in women with PPD, now designated a pivotal trial.
- Business Wire•12 days ago
Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M.
- Business Wire•16 days ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 59,600 shares of its common stock to eleven new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Market Realist•20 days ago
Sage’s Brexanolone IV: FDA Grants Priority Review
Sage Therapeutics (SAGE) is a US-based clinical-stage biopharmaceutical company. On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV. The FDA granted a priority review for the drug. Following the news, the stock price increased ~1.8% to the closing price of $154.54 on May 30.
- Business Wire•21 days ago
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for Sage’s lead product candidate, an intravenous formulation of brexanolone (SAGE-547) for the treatment of postpartum depression (PPD). The NDA was granted Priority Review status and the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of December 19, 2018. As expected for a new molecular entity with a new mechanism of action, the FDA is currently planning to hold an advisory committee meeting to discuss the brexanolone IV application.
- Motley Fool•27 days ago
Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
The tiny biopharma is back on the upswing following an analyst upgrade.
- Business Wire•28 days ago
Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at Bernstein’s 34th Annual Strategic Decisions Conference on Wednesday, May 30, 2018 at 11:00 A.M.
- Market Realist•last month
Why Wall Street Analysts Are Mostly Positive on CRISPR
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
- Business Wire•last month
Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that members of the Sage management team will participate in a fireside chat presentation at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 3:40 P.M.
